Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsIn the fast-paced world of therapeutic antibody development, diagnostics, and biological research, the precise amino acid sequence of a monoclonal antibody (mAb) is the cornerstone of its characterization, intellectual property (IP) protection, and engineering potential. Creative Biolabs stands at the forefront of protein sequencing, offering state-of-the-art De Novo Antibody Sequencing services that deliver unparalleled accuracy and comprehensive coverage. Leveraging our proprietary Database Assisted Shotgun Sequencing (DASS) technology and advanced mass spectrometry platforms, we can elucidate the complete, correct sequence of any monoclonal antibody, including the variable (V) and constant (C) regions of both heavy and light chains. Our technology ensures the unambiguous discrimination of leucine and isoleucine, a critical challenge that eludes many standard sequencing methods. We provide an end-to-end solution for researchers who have lost their hybridoma cell line, need to characterize a competitor's antibody, or require a precise digital blueprint for antibody engineering and manufacturing.
At Creative Biolabs, we have refined de novo antibody sequencing into a science of absolute certainty. Our commitment to 100% accuracy in antibody sequencing is not just a goal; it is a guarantee backed by decades of expertise and cutting-edge technology.
Fig. 1 MS-based de novo sequencing solution of monoclonal antibodies.1
Our sequencing workflow is a meticulously designed process that combines robust biochemistry with powerful bioinformatic analysis, designed for unrivaled precision in de novo antibody sequencing.
Workflow Breakdown
Creative Biolabs offers a suite of specialized de novo sequencing services tailored to meet the diverse needs of our clients.
The functional core of an antibody lies in its variable (V) regions, but the constant (C) regions are equally important for effector functions and manufacturability. Our Database Assisted Shotgun Sequencing (DASS) technology provides a powerful hybrid approach. For the highly conserved framework and constant regions (V, J, and C segments), we leverage comprehensive species-specific antibody databases to rapidly confirm peptide sequences. This strategy enhances the speed and confidence of assembly, allowing our powerful de novo algorithms to focus computational power on deciphering the most critical and unique region: the CDR3.
The Complementarity-Determining Region 3 (CDR3) is the most variable part of an antibody and is typically the primary driver of its binding specificity and affinity. Its unique sequence and length present a significant challenge for standard sequencing methods. Our high-resolution mass spectrometers and specialized fragmentation techniques are optimized to handle the complexity of the CDR3 loop, ensuring every amino acid is correctly identified and placed, providing a flawless sequence for this critical region.
Many research and diagnostic antibodies are conjugated to fluorochromes or exist in complex formats like pentameric IgMs. These modifications and structures can interfere with sequencing.
Leucine (L) and Isoleucine (I) have identical molecular masses, making them indistinguishable by standard mass spectrometry. An error in this assignment can lead to a non-functional or altered antibody upon synthesis. Creative Biolabs has mastered techniques to overcome this fundamental limitation. We employ advanced fragmentation methods like Electron-Transfer/Higher-Energy Collision Dissociation (EThcD) that cleave peptide side chains, generating specific fragment ions (w-ions and d-ions) that are unique to leucine or isoleucine. This provides definitive, unambiguous identification, underpinning our promise of 100% accuracy in antibody sequencing.
A precise antibody sequence is an invaluable asset across numerous research and development applications.
| Application Area | How De Novo Sequencing Provides Value |
| Hybridoma Cell Line Rescue | Resurrect valuable monoclonal antibodies from unstable or lost hybridoma lines. |
| Antibody Drug Development | Provide the foundational sequence for antibody humanization, affinity maturation, and developability assessment. |
| Intellectual Property (IP) & Patents | Secure patent protection by defining the exact composition of matter of your antibody therapeutic or diagnostic tool. |
| Competitor Analysis | Reverse engineer and characterize a competitor's antibody product for biosimilar or biobetter development. |
| Manufacturing & QC | Verify the sequence of antibody batches to ensure consistency and identify any production errors. |
| Research & Tool Antibody Validation | Confirm the identity of commercial or in-house antibodies to ensure reproducibility of experimental results. |
To further support your research, Creative Biolabs offers a suite of antibody sequencing related services:
Don't let an unknown sequence be the bottleneck in your research. Trust the experts at Creative Biolabs for guaranteed, publication-quality de novo antibody sequencing. Our dedication to 100% accuracy, particularly in the discrimination of leucine & isoleucine, ensures that the sequence you receive is the true sequence of your antibody.
Q: How do you guarantee 100% accuracy?
A: Our guarantee is based on our deep sequencing coverage and orthogonal methods. We use multiple enzymes to create overlapping peptides, ensuring every amino acid is sequenced multiple times. The final assembled sequence is also cross-validated by confirming that its theoretical mass matches the experimentally measured intact mass of the antibody's heavy and light chains.
Q: Can you sequence antibodies from any species?
A: Yes. Our de novo approach is species-independent. We have successfully sequenced antibodies from a wide range of species, including mouse, rat, rabbit, hamster, chicken (IgY), and even more exotic species for which genomic databases are unavailable.
Q: Can you identify post-translational modifications (PTMs)?
A: Absolutely. Our high-resolution mass spectrometry platform is adept at identifying common PTMs such as glycosylation, oxidation, deamidation, and pyroglutamate formation. We can provide a detailed map of these modifications on your antibody.
Q: What is the difference between de novo protein sequencing and DNA sequencing of hybridomas?
A: This is a critical distinction. DNA sequencing of a hybridoma cell line determines the genetic blueprint for the antibody. However, it cannot confirm the sequence of the actual, expressed protein. Discrepancies can arise from transcription/translation errors or post-translational modifications. Furthermore, if the cell line is lost, unstable, or unavailable, DNA sequencing is not an option.
Our de novo antibody sequencing service analyzes the final protein product directly. This provides the "ground truth" amino acid sequence of the functional antibody, making it the most accurate and reliable method for characterization, patent filing, and ensuring successful recombinant production.
Q: Why is the discrimination between Leucine (L) and Isoleucine (I) so important?
A: Leucine and Isoleucine have identical masses and are therefore indistinguishable by standard mass spectrometry. However, they are structurally different amino acids. An incorrect assignment in a critical region like a CDR can lead to a recombinantly produced antibody with reduced affinity, altered specificity, or a complete loss of function. By guaranteeing the correct assignment, we ensure that the sequence you receive will produce a functionally identical antibody, protecting your investment and accelerating your research.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
